Cabaletta Bio (CABA) Expected to Announce Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) will likely be releasing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Cabaletta Bio to post earnings of ($0.52) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:00 AM ET.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.02). On average, analysts expect Cabaletta Bio to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cabaletta Bio Price Performance

NASDAQ CABA opened at $2.61 on Thursday. The company has a market capitalization of $238.71 million, a PE ratio of -0.96 and a beta of 3.10. The company has a fifty day moving average of $2.30 and a 200 day moving average of $1.87. Cabaletta Bio has a 1 year low of $0.99 and a 1 year high of $5.46.

Institutional Investors Weigh In On Cabaletta Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. grew its stake in Cabaletta Bio by 142.9% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock valued at $13,421,000 after acquiring an additional 5,195,285 shares in the last quarter. Marshall Wace LLP grew its stake in Cabaletta Bio by 470.7% during the 2nd quarter. Marshall Wace LLP now owns 190,957 shares of the company’s stock valued at $290,000 after acquiring an additional 157,497 shares in the last quarter. Invesco Ltd. grew its stake in Cabaletta Bio by 37.5% during the 2nd quarter. Invesco Ltd. now owns 84,831 shares of the company’s stock valued at $129,000 after acquiring an additional 23,156 shares in the last quarter. XTX Topco Ltd purchased a new stake in Cabaletta Bio during the 2nd quarter valued at about $148,000. Finally, AQR Capital Management LLC purchased a new stake in Cabaletta Bio during the 1st quarter valued at about $102,000.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CABA. Cantor Fitzgerald boosted their target price on shares of Cabaletta Bio from $15.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday, October 8th. Jefferies Financial Group began coverage on shares of Cabaletta Bio in a research report on Friday, October 10th. They set a “buy” rating and a $14.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Cabaletta Bio in a research report on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.11.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.